Gergana Galabova

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

Christine Landlinger, Marianne Pouwer, Claudia Juno et al. · European Heart Journal · 2017 · 221 citations · Full text

Veterinary Medicine, Immunology, Pharmacology +17

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial

Dieter Volc, Werner Poewe, Alexandra Kutzelnigg et al. · The Lancet Neurology · 2020 · 145 citations

Life Sciences, Neurology, Neuroscience +11

Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management

Gergana Galabova, Sylvia Brunner, Gabriele Winsauer et al. · PLoS ONE · 2014 · 136 citations · Full text

Pharmacy, Cardiology, Immunology +17

A Phase 1 Randomized Trial of Specific Active <scp>α‐Synuclein</scp> Immunotherapies <scp>PD01A</scp> and <scp>PD03A</scp> in Multiple System Atrophy

Wassilios G. Meissner, Anne Pavy‐Le Traon, Alexandra Foubert‐Samier et al. · Movement Disorders · 2020 · 84 citations · Full text

Life Sciences, Neurology, Neuroscience +16

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study

Klaus Seppi, Rossella Medori, Petra Lührs et al. · Journal of Parkinson s Disease · 2021 · 62 citations · Full text

Life Sciences, Immunology, Neurology +17